Abdul Rahman Khalifeh

Contributor

tags:   Immunotherapy    

Disclaimer: All opinions, ideas, and thoughts expressed and posted by Contributors at BiopharmaTrend.com platform are their own personal points of view, and do not represent neither Contributor's employers, nor BiopharmaTrend.com.

Posts by this author

IgGenix Demonstrates Potential for Single-Cell RNA-Sequencing in Tree Nut Allergies

   157
IgGenix Demonstrates Potential for Single-Cell RNA-Sequencing in Tree Nut Allergies

SOUTH SAN FRANCISCO, Calif. – July 1, 2022 – IgGenix, Inc., a biotechnology company taking a revolutionary approach to directly alleviate allergic disease, today announced insights from its novel SeqSifter™ single-cell RNA-sequencing discovery platform demonstrating the potential for IgE antibody re-engineering in tree nut allergy. These data will be presented during the 2022 European Academy of Allergy and Clinical Immunology (EAACI) Hybrid Congress, taking place in Prague, Czech Republic on July 1-3, 2022.